Zealand Pharma AS (XTER:22Z) Cyclically Adjusted PS Ratio: (As of Sep. 02, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTER:22Z Zealand Pharma AS XTER:22Z
45 GF Score
Price €41.21
! 7 Warning Signs
View Full Analysis

What is Zealand Pharma AS Cyclically Adjusted PS Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PS Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Zealand Pharma AS  (XTER:22Z) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Zealand Pharma AS Cyclically Adjusted PS Ratio Related Terms


Zealand Pharma AS Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Zealand Pharma AS's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zealand Pharma AS Cyclically Adjusted PS Ratio Chart

Zealand Pharma AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.98 39.48 67.04 143.74 26.44

Zealand Pharma AS Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.35 24.93 26.44 16.65 11.80

XTER:22Z vs VRTX, REGN, MRNA: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Zealand Pharma AS's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zealand Pharma AS Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zealand Pharma AS's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Zealand Pharma AS's Cyclically Adjusted PS Ratio falls into.


XTER:22Z
45GF Score
Zealand Pharma AS XTER:22Z
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zealand Pharma AS Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Zealand Pharma AS's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Zealand Pharma AS's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=8.486/333.9520*333.9520
=8.486

Current CPI (Jun. 2026) = 333.9520.

Zealand Pharma AS Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.221 241.428 0.306
201612 0.928 241.432 1.284
201703 0.399 243.801 0.547
201706 0.052 244.955 0.071
201709 0.184 246.819 0.249
201712 0.044 246.524 0.060
201803 0.043 249.554 0.058
201806 0.066 251.989 0.087
201809 0.000 252.439 0.000
201812 0.057 251.233 0.076
201903 0.000 254.202 0.000
201906 0.084 256.143 0.110
201909 0.040 256.759 0.052
201912 0.042 256.974 0.055
202003 0.046 258.115 0.060
202006 0.798 257.797 1.034
202009 0.191 260.280 0.245
202012 -0.325 260.474 -0.417
202103 0.018 264.877 0.023
202106 0.114 271.696 0.140
202109 0.169 274.310 0.206
202112 0.042 278.802 0.050
202203 0.034 287.504 0.039
202206 0.077 296.311 0.087
202209 0.127 296.808 0.143
202212 0.063 296.797 0.071
202303 0.036 301.836 0.040
202306 0.024 305.109 0.026
202309 0.657 307.789 0.713
202312 0.053 306.746 0.058
202403 0.033 312.332 0.035
202406 0.073 314.175 0.078
202409 0.008 315.301 0.008
202412 0.017 315.605 0.018
202503 0.015 319.799 0.016
202506 16.986 322.561 17.586
202509 0.094 324.800 0.097
202512 0.129 324.054 0.133
202603 0.064 330.213 0.065
202606 8.486 333.952 8.486

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Zealand Pharma AS Business Description

Address Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
45GF Score

Get the complete analysis for XTER:22Z

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€41.21
Price